|86.76||+0.2600||+0.30%||Vol 370.66K||1Y Perf 185.31%|
|Sep 15th, 2021 16:00 DELAYED|
|- -%||- -|
|Target Price||141.00||Analyst Rating||Strong Buy 1.00|
|Potential %||62.52||Finscreener Ranking||★★★★★ 68.13|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||★★★★★ 70.44|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||★★★★★ 89.81|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||35.52||Earnings Rating||Neutral|
|Market Cap||2.56B||Earnings Date||8th Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|3 Years||2 371.79%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||8th Nov 2021|
|Estimated EPS Next Report||1.29|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||561.26K|
|Avg. Monthly Volume||494.30K|
|Avg. Quarterly Volume||700.31K|
Fulgent Genetics Inc. (NASDAQ: FLGT) stock closed at 86.76 per share at the end of the most recent trading day (a 0.3% change compared to the prior day closing price) with a volume of 371.39K shares and market capitalization of 2.56B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 139 people. Fulgent Genetics Inc. CEO is Ming Hsieh.
The one-year performance of Fulgent Genetics Inc. stock is 185.31%, while year-to-date (YTD) performance is 66.53%. FLGT stock has a five-year performance of %. Its 52-week range is between 29.95 and 189.89, which gives FLGT stock a 52-week price range ratio of 35.52%
Fulgent Genetics Inc. currently has a PE ratio of 5.20, a price-to-book (PB) ratio of 3.03, a price-to-sale (PS) ratio of 2.84, a price to cashflow ratio of 5.80, a PEG ratio of 2.32, a ROA of 85.74%, a ROC of 96.32% and a ROE of 98.24%. The company’s profit margin is 54.29%, its EBITDA margin is 72.70%, and its revenue ttm is $909.74 Million , which makes it $30.82 revenue per share.
Of the last four earnings reports from Fulgent Genetics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $1.29 for the next earnings report. Fulgent Genetics Inc.’s next earnings report date is 08th Nov 2021.
The consensus rating of Wall Street analysts for Fulgent Genetics Inc. is Strong Buy (1), with a target price of $141, which is +62.52% compared to the current price. The earnings rating for Fulgent Genetics Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Fulgent Genetics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Fulgent Genetics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.20, ATR14 : 5.11, CCI20 : -139.52, Chaikin Money Flow : -0.13, MACD : -1.28, Money Flow Index : 49.52, ROC : -6.77, RSI : 42.07, STOCH (14,3) : 11.64, STOCH RSI : 0.05, UO : 35.90, Williams %R : -88.36), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Fulgent Genetics Inc. in the last 12-months were: Han Lin Gao (Sold 930 shares of value $65 822 ), Jian Xie (Sold 90 525 shares of value $8 029 278 ), John C. Bolger (Option Excercise at a value of $40 790), John C. Bolger (Sold 9 956 shares of value $703 526 ), Paul Kim (Sold 194 388 shares of value $10 072 216 )
Thu, 02 Sep 2021 07:22 GMT What Does Fulgent Genetics Newly Added Risk Factor Tell Investors- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.